Insulet PODD Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 71%+0.6pp | 71.6%+1.8pp | 71.5%+2.1pp | 70.7%+1.7pp | 70.4%+1.5pp | |
| Operating margin | 17.5%+2.0pp | 17.5%+2.6pp | 17.3%+1.9pp | 17.3%+2.7pp | 15.5%+1.5pp | |
| Net margin | 10.4%-7.9pp | 9.1%-11.1pp | 9.8%-11.5pp | 10%-11.1pp | 18.3%+5.2pp | |
| EBITDA margin | 20.8%+1.5pp | 20.8%+2.0pp | 20.8%+1.4pp | 20.9%+2.3pp | 19.3%+1.1pp | |
| Free cash flow margin | 14.3%+1.1pp | 13.9%-0.8pp | 16.8%+5.3pp | 17.2%+7.5pp | 13.2%+5.1pp | |
| Returns | ||||||
| Return on equity | 23%-14.9pp | 18.1%-24.9pp | 19.7%-29.1pp | 19.2%-31.7pp | 37.9%+1.7pp | |
| Return on assets | 9.3%-3.8pp | 7.9%-6.9pp | 8.1%-7.2pp | 7.4%-7.6pp | 13.1%+3.6pp | |
| Return on invested capital | 21%+0.6pp | 19%+0.6pp | 21.2%+1.7pp | 19.3%+0.7pp | 20.4%+3.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×+0.2× | 0.9×+0.1× | 0.8×+0.1× | 0.7×0.0× | 0.7×0.0× | |
| Inventory turnover | 1.9×+0.4× | 1.7×+0.2× | 1.6×+0.2× | 1.6×+0.2× | 1.5×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.5×-2.0× | 2.8×-0.8× | 2.9×-0.8× | 2.3×-1.3× | 4.5×+0.7× | |
| Quick ratio | 1.8×-1.8× | 2.1×-0.6× | 2.2×-0.6× | 1.8×-0.9× | 3.6×+0.9× | |
| Cash ratio | 0.7×-1.8× | 1.1×-0.8× | 1.2×-0.6× | 1.1×-0.6× | 2.5×+0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.7×-0.6× | 0.7×-0.6× | 0.8×-0.5× | 1.3×-0.2× | 1.3×-0.5× | |
| Debt-to-assets | 0.3×-0.2× | 0.3×-0.2× | 0.4×-0.1× | 0.5×0.0× | 0.5×-0.1× | |
| Net debt / EBITDA | 0.8×-0.4× | 0.5×-1.0× | 0.6×-0.9× | 1.5×-0.4× | 1.2×-1.1× | |
| Interest coverage | 7.8×-0.4× | 8×+0.8× | 8.2×+0.7× | 8.2×+1.2× | 8.3×+1.6× | |
| Per Share | ||||||
| Book value per share | $18.56+3.3% | $21.08+28.5% | $19.59+29.6% | $20.71+53.1% | $17.95+67.4% | |
| Valuation | ||||||
| Market capitalization | $14.77B-19.9% | $20B+9.2% | $21.73B+33.3% | $21.88B+55.0% | $18.44B+54.0% | |
| Enterprise value | $15.26B-19.4% | $20.3B+7.4% | $22.07B+30.7% | $22.62B+53.2% | $18.94B+49.2% | |
| Price / earnings | 48.8×+2.9× | 80.9×+37.1× | 88.3×+49.5× | 92.7×+57.0× | 45.9×-5.3× | |
| Price / sales | 5.1×-3.3× | 7.4×-1.5× | 8.6×+0.4× | 9.3×+1.7× | 8.4×+1.7× | |
| Price / book | 11.3×-2.5× | 13.2×-1.9× | 15.7×+1.1× | 15×+0.8× | 13.9×-1.3× | |
| EV / EBITDA | 25.3×-19.3× | 36×-12.6× | 42.1×-1.9× | 45.8×+3.4× | 44.6×+5.4× | |
| EV / sales | 5.3×-3.4× | 7.5×-1.6× | 8.8×+0.2× | 9.6×+1.7× | 8.6×+1.5× | |
| Free cash flow yield | 2.8%+1.2pp | 1.9%+0.2pp | 1.9%+0.6pp | 1.9%+0.6pp | 1.6%+0.4pp | |
| Earnings yield | 2%-0.1pp | 1.2%-1.0pp | 1.1%-1.4pp | 1.1%-1.7pp | 2.2%+0.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insulet's profit margins?
- Insulet (PODD) runs a 71.0% gross margin and a 17.5% operating margin, with a 10.4% net margin.
- Where do Insulet's ratios come from?
- Every ratio is computed from Insulet's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
